Tauklarify is a PET imaging agent that detects tau tangle buildup in the brain, and in 2026 it gives people with mild cognitive impairment (MCI) a second scan option alongside blood-based tests that cost far less. The right choice depends on budget, scanner access, and whether a doctor needs confirmatory imaging or just an early screen. The FDA approved Tauklarify, known generically as florquinitau F-18 (also called MK-6240), on August 14, 2026, as a PET tracer for detecting tau neurofibrillary tangle pathology in adults undergoing evaluation for Alzheimer's disease, according to Lantheus and Healio's coverage of the approval. For patients with MCI trying to understand what is driving their memory or thinking changes, that scan now sits next to a newer option: a simple blood draw that measures tau-related proteins.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What Tauklarify Is and Who It's For
- How Accurate Is a Tauklarify Scan?
- How Blood Tests Compare on Accuracy
- Cost and Access Differences
- How to Decide Between the Two
- Frequently Asked Questions
What Tauklarify Is and Who It's For
Tauklarify is only the second tau PET tracer the FDA has approved, following Eli Lilly's flortaucipir F-18 (Tauvid), according to the Society of Nuclear Medicine and Molecular Imaging (SNMMI). That gives clinicians evaluating patients with MCI a choice of tau tracers rather than relying on one tracer or amyloid PET alone. The approval was supported by trials that scanned more than 500 subjects across three studies, covering people with MCI, mild Alzheimer's dementia, and cognitively unimpaired controls.
One report puts the combined total at 617 subjects, with 157 of them classified as having mild cognitive impairment, according to coverage of the FDA decision in Psychiatric Times. Tauklarify is not approved for evaluating tauopathies outside of Alzheimer's disease, so it has a narrow, specific use: confirming or ruling out tau tangle pathology in someone already being worked up for Alzheimer's. Side effects were rare in trials — headache and injection-site reactions occurred in fewer than 1% of subjects given the standard dose of about 185 MBq (5 mCi) by IV, according to Applied Radiology's reporting on the SNMMI announcement.
How Accurate Is a Tauklarify Scan?
Across two blinded-read accuracy studies, Tauklarify showed positive percent agreement of 68%-88% and negative percent agreement of 93%-99% against a reference standard, according to Healio's report on the approval. In plain terms, the scan is better at correctly ruling out tau pathology than at catching every true case.
That accuracy was established mainly by comparing amyloid-negative, cognitively unimpaired subjects against amyloid-positive, impaired subjects — a narrower comparison than the full range of MCI presentations clinicians see day to day. A patient whose MCI sits in a grayer zone, without a clear-cut amyloid or impairment status, may fall outside the range where these agreement numbers were measured most precisely.
How Blood Tests Compare on Accuracy
A pooled 2026 analysis covering nine cohorts and 1,474 cognitively normal and at-risk adults, with a mean age of 69 and about four years of follow-up, found that plasma p-tau217 blood tests performed about as well as tau PET scans at predicting progression to MCI. Each method explained roughly a third of the variance in future cognitive decline, according to a Carlat Report summary of the Ossenkoppele et al. analysis.
A separate 2026 study built a two-tau-protein blood model and tested it on more than 1,000 people, including those with MCI. Its disease-staging results closely matched PET brain scans, though outside experts described the findings as promising rather than proven, and said the model needs confirmation in larger, independent studies before blood tests can substitute for PET staging, according to HealthDay's coverage of the research. Eli Lilly also reported at AAIC 2026 that its own P-tau217 blood assay showed rule-in performance for Alzheimer's pathology comparable to amyloid PET in cognitively unimpaired adults. That company-sponsored data supports using a blood test as a scalable first screen before confirmatory PET imaging such as Tauklarify, according to Lilly's press release distributed via BioSpace.
Cost and Access Differences
The practical gap between these two options is largest on cost and availability. A tau PET scan runs around $5,000 and depends on limited scanner availability at specialized imaging centers, while a plasma p-tau217 blood test costs roughly $200-$400 and only requires a standard blood draw, according to the Carlat Report's summary of the pooled cohort analysis. That cost and access difference is why blood testing is emerging as the more accessible first-line option for most patients with cognitive concerns, with PET reserved for cases needing a more detailed, confirmatory picture of tau burden and its location in the brain.
How to Decide Between the Two
For a patient with MCI and a care partner weighing these options, a few practical questions help sort out which path fits: A reasonable sequence many clinicians are moving toward is blood testing first, with a tau PET scan like Tauklarify ordered afterward if results are ambiguous or a definitive tau-burden picture is needed before starting treatment decisions.
- Is a neurologist ordering this as a first screen, or to confirm a diagnosis already suspected from symptoms and other testing? A blood test fits the first case; PET fits the second.
- Is there a PET scanner with tau tracer availability nearby? Many areas still lack ready access, which pushes blood testing forward by default.
- Does insurance or out-of-pocket budget favor the $200-$400 blood test over the roughly $5,000 PET scan?
- Does the clinical picture fall within the amyloid-positive/impaired versus amyloid-negative/unimpaired contrast where Tauklarify's accuracy data is strongest, or is it a borderline case where a scan's agreement rates are less certain?
- Is the question limited to Alzheimer's-type tau pathology? Tauklarify is not approved for evaluating other tauopathies, so a different workup applies if a clinician suspects a non-Alzheimer's tau disorder.
Frequently Asked Questions
Does a Tauklarify scan replace the need for a blood test?
No. They answer different questions — blood tests like plasma p-tau217 are typically used as an accessible first screen, while Tauklarify gives a detailed, confirmatory picture of tau tangle location and burden once ordered by a clinician.
Can Tauklarify diagnose tauopathies other than Alzheimer's disease?
No. The FDA approval covers detecting tau neurofibrillary tangle pathology specifically in adults being evaluated for Alzheimer's disease, not other tau-related conditions.
Why is there a mention of Eli Lilly in an article about Tauklarify, which is a different company's product?
Lilly's P-tau217 blood assay data, presented at AAIC 2026, is relevant context because it shows blood testing can rule in Alzheimer's pathology with accuracy comparable to amyloid PET, supporting its role as a triage step before a confirmatory scan such as Tauklarify.
You Might Also Like
- Tauklarify Tau PET vs Amyloid PET After the 2026 Approval: How People With Mild Cognitive Impairment Can Compare Testing Options
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: How People With Mild Cognitive Impairment Can Compare Testing Options
- FDA’s 2026 Tauklarify Tau PET Imaging Approval: How People With Mild Cognitive Impairment Can Compare Testing Options
